Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Mesothelioma, Malignant 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumor, Pleural 1Small Cell Lung Carcinoma 1Sarcoma 1Oropharyngeal Neoplasms 1Metastatic NUT Carcinoma 1Melanoma 1Colorectal Neoplasms 1Cervical Adenocarcinoma 1Bone Neoplasms 1Advanced NUT Carcinoma 1

Interventions

Etoposide 18Carboplatin 18pembrolizumab 15Nivolumab 11Cisplatin 11atezolizumab 8Topotecan 8Irinotecan 7Temozolomide 6Paclitaxel 5PM 01183 5Ipilimumab 5Gemcitabine 5olaparib 4Radiotherapy 4Docetaxel 4surufatinib 3durvalumab 3carfilzomib 3Bevacizumab 3veliparib 2trilaciclib 2sacituzumab govitecan 2rovalpituzumab tesirine 2obatoclax 2niraparib 2navitoclax 2lorvotuzumab mertansine 2lenvatinib 2fluzoparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Small Cell Lung Carcinoma × 1,2-diaminocyclohexaneplatinum II citrate × Clear all
NCT00453154 2023-04-04

Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
156 enrolled 14 charts
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡